Skip to content
DataLookout
Menu

EPIK-P2NCT04589650

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 40 versions: 38 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment increased: 206 → 236 participants Show 5 more changesShow less
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 17 of 22 entries
    • Study sites revised (36)
    • Publications: details revised at 2 of 2 entries
    • Study description expanded, about 2 words
  2. Minor Site details revised at 3 of 36 sitesv39
  3. Minor Site details revised at 1 of 36 sitesv38
  4. Minor Enrollment target: 203 to 206
    • Study completion date: Jan 17, 2031 to Jan 9, 2031
    • Site details revised at 2 of 36 sites
    v36
  5. Minor Enrollment target: 200 to 203
    • Site details revised at 1 of 36 sites
    v35
Show 32 earlier versionsHide 32 earlier versions
  1. Minor Enrollment target: 205 to 200
    • Study completion date: Feb 28, 2031 to Jan 17, 2031
    • Study description expanded, about 557 words
    • Study sites revised (36)
    v34
  2. Minor Study sites: 35 to 36v33
  3. Minor Study sites: 36 to 35
    • Study completion date: Feb 21, 2031 to Feb 28, 2031
    v32
  4. Minor Study completion date: Feb 14, 2031 to Feb 21, 2031
    • Site details revised at 1 of 36 sites
    v31
  5. Minor Enrollment target: 188 to 205
    • Site details revised at 5 of 36 sites
    v30
  6. Notable Results first posted: Feb 10, 2025v29 Show 7 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 205 to confirmed 188
    • Study sites: 39 to 36
    • Study completion date: Apr 28, 2031 to Feb 14, 2031
    • Secondary endpoints revised (22)
    • Primary endpoint revised
    • Study description shortened, about 3 words
  7. Minor Eligibility criteria expanded, about 240 words
    • Secondary endpoints revised (22)
    • Study description expanded, about 52 words
    • Study sites revised (39)
    v28
  8. Minor Site details revised at 2 of 39 sitesv27
  9. Minor Enrollment target: 189 to 205
    • Study completion date: Mar 27, 2031 to Apr 28, 2031
    • Site details revised at 1 of 39 sites
    v26
  10. Minor Study sites revised (39)v25
  11. Minor Study completion date: Mar 11, 2031 to Mar 27, 2031
    • Study sites revised (39)
    v24
  12. Minor Primary completion date changed from estimate of Jun 7, 2030 to Mar 20, 2024
    • Study completion date: Jun 7, 2030 to Mar 11, 2031
    • Study sites revised (39)
    v23
  13. Minor Site details revised at 3 of 39 sitesv22
  14. Minor Study sites revised (39)v21
  15. Minor Study description revised
    • Study sites revised (39)
    v20
  16. Notable Primary and study completion dates pushed to Jun 7, 2030v19
  17. Minor Study sites revised (39)v18
  18. Minor Primary completion date: Jun 8, 2023 to Sep 20, 2023v17
  19. Minor Eligibility criteria expanded, about 75 words
    • Site details revised at 3 of 39 sites
    v16
  20. Notable Primary endpoint revisedv15 Show 8 more changesShow less
    • Enrollment target: 174 to 189
    • Study sites: 33 to 39
    • Primary completion date: Mar 27, 2023 to Jun 8, 2023
    • Study completion date: Dec 26, 2029 to Feb 25, 2030
    • Secondary endpoints: 20 to 22
    • Study description expanded, about 27 words
    • Study arms: 6 to 7
    • Eligibility criteria expanded, about 2 words
  21. Minor Study sites: 31 to 33v13
  22. Minor Site contacts updated at 1 of 31 sitesv12
  23. Minor Study sites: 30 to 31v11
  24. Minor Enrollment target: 150 to 174
    • Study sites: 26 to 30
    v10
  25. Minor Study sites: 25 to 26v9 Show 4 more changesShow less
    • Eligibility criteria expanded, about 135 words
    • Secondary endpoints: 19 to 20
    • Study description expanded, about 58 words
    • Study arms: 5 to 6
  26. Minor Study sites: 21 to 25v8
  27. Minor Study sites: 15 to 21v7
  28. Minor Study sites: 9 to 15v6
  29. Minor Study sites: 4 to 9v5
  30. Minor Study sites: 2 to 4v4
  31. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Mar 31, 2021 to Apr 19, 2021
    v3
  32. Notable Start date: Feb 2, 2021 to Mar 31, 2021
    • Primary completion date: Jan 27, 2023 to Mar 27, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 2
Timeframe: Up to 48 weeks

Secondary (22)

Key Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 2
Proportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 2
Frequency and Severity of Adverse Events in Groups 1 and 2 up to Week 16
Frequency and Severity of Adverse Events in All Groups of Participants Over Time
Change From Baseline to Week 16 in Brief Pain Inventory (BPI) Worst Pain Intensity in Group 1 and 2
Show 17 moreShow less
Number of Participants With Global Impression of Symptom Severity (PGIS) Score up to Week 16
Percentage Change From Baseline in Target and MRI-measurable Non- Target Lesion Volume in Group 1 and Group 2
Proportion of Participants With Changes From Baseline in Other Non-target Lesions in Group 1 and Group 2
Proportion of Participants With New Lesions in Group 1 and Group 2
Pharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Maximum Concentration (Cmax)
Pharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Trough Concentration (Ctrough)
Change From Baseline in Patient-reported Pain Assessed by Brief Pain Inventory (BPI) Worst Pain Intensity Item or Wong-Baker Faces Scale (Age Appropriate) in Pediatric and Adult Populations
Changes From Baseline in Patient-reported Health-related Quality of Life Assessed by PROMIS-profile (Patient Reported Outcome Measurement Information System) in Pediatric and Adult Populations
Changes From Baseline in Patient-reported Overall Impression of Symptoms Assessed by Patient Global Impression of Symptom Severity (PGIS) in Pediatric and Adult Populations
Duration of Response (DOR) in Participants Who Received Alpelisib in Group 1 and Group 2
Time to Treatment Failure in Participants Who Received Alpelisib in Group 1 and Group 2
Overall Clinical Response Rate as Assessed by Investigator in Participants Who Received Alpelisib in Group 1 and Group 2
Proportion of Participants With Response During the Extension Period in Group 1 and Group 2
Changes in Symptoms and Complications/Comorbidities up to Week 16 on Treatment With Alpelisib as Compared to Placebo in Group 1 and Group 2
Changes in Symptoms and Complications/Comorbidities Associated With PROS Over Time in Group 1 and Group 2
Proportion of Participants With Healthcare Visit/Hospitalized Due to PROS in Group 1 and Group 2
Proportion of Participants Requiring Rescue Surgery Due to PROS in Group 1 and Group 2

Arms and interventions

Adult cohort (group 1)- AlpelisibExperimental

During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.

Adult cohort (group 1)- PlaceboPlacebo comparator

During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.

Pediatric cohort (group 2: 6 to 17 years old) -AlpelisibExperimental

During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.

Pediatric cohort (group 2: 6 to 17 years old)-PlaceboPlacebo comparator

During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.

Pediatric cohort (group 3: 0 to 5 years old)- Alpelisib granulesExperimental

Pediatric participants (0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose (\<1 month: 20 mg every other day; 1 to \<6 months: 20 mg daily; 6 to \<2 years: 40 mg daily; 2 to \<6 years: 50 mg daily).

Pediatric cohort (group 4: 2 to 5 years old)- Alpelisib FCTExperimental

Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.

Pediatric cohort (group 5: 6-17 years old)-Alpelisib FCTExperimental

Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.

Drugs: Alpelisib, Placebo

Sites

36 sites in 12 countries

United States 11, Germany 5, France 4, United Kingdom 3, Canada 2, China 2, Italy 2, Spain 2, Switzerland 2, Hong Kong 1, Netherlands 1, Norway 1